Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Joseph C, Gathe"'
Autor:
CLAUDIA RAMIREZ, MOHAMED ZIAD, SUSHEN BHALLA, JESUS SALVADOR GONZALEZ LOPEZ, AILINE CANETE CRUZ, ANGELICA ALMAGUER, NDIYA EMEABA, DAVID AKINWALE, NAJIA N. HUSSAINI, DARYELLE S VARON, JOSEPH C GATHE, SALIM R SURANI, JOSEPH VARON
Publikováno v:
Chest. 162:A859-A860
Autor:
SUSHEN BHALLA, CLAUDIA RAMIREZ, MOHAMED ZIAD, ANGELICA ALMAGUER, AILINE CANETE CRUZ, JESUS SALVADOR GONZALEZ LOPEZ, NDIYA EMEABA, DAVID AKINWALE, NAJIA N. HUSSAINI, DARYELLE S VARON, JOSEPH C GATHE, SALIM R SURANI, JOSEPH VARON
Publikováno v:
Chest. 162:A861-A862
Autor:
ANGELICA ALMAGUER, CLAUDIA RAMIREZ, MOHAMED ZIAD, SUSHEN BHALLA, AILINE CANETE CRUZ, JESUS SALVADOR GONZALEZ LOPEZ, NDIYA EMEABA, DAVID AKINWALE, NAJIA N. HUSSAINI, DARYELLE S VARON, JOSEPH C GATHE, SALIM R SURANI, JOSEPH VARON
Publikováno v:
Chest. 162:A865-A866
Autor:
MOHAMED ZIAD, CLAUDIA RAMIREZ, ANGELICA ALMAGUER, SUSHEN BHALLA, JESUS SALVADOR GONZALEZ LOPEZ, AILINE CANETE CRUZ, NDIYA EMEABA, DAVID AKINWALE, NAJIA N. HUSSAINI, DARYELLE S VARON, JOSEPH C GATHE, SALIM R SURANI, JOSEPH VARON
Publikováno v:
Chest. 162:A863-A864
Autor:
Joseph C. Gathe MD, FACP, FIDSA, Efemena M. Diejomaoh MBBS, Carl C. Mayberry PA, John B. Clemmons MD
Publikováno v:
Journal of the International Association of Providers of AIDS Care, Vol 15 (2016)
Clostridium difficile is a gram-positive bacterium that is recognized as a causative organism of pseudomembranous enterocolitis. This infection has become a major public health challenge and is a source of considerable morbidity and mortality in thos
Externí odkaz:
https://doaj.org/article/4a297dfdd9c14f6da69792e0dbebedfb
Autor:
Joseph Varon, Daryelle S. Varon, Joseph C. Gathe, Valeria Demeneghi Aleman, Estrella Fernández, Salim Surani
Publikováno v:
Chest
SESSION TITLE: Cultural Diversity Posters SESSION TYPE: Original Investigation Posters PRESENTED ON: October 18-21, 2020 PURPOSE: Health is greatly influenced by the resources of the population, and social determinants of health have always played a
Autor:
David L, Wyles, Peter J, Ruane, Mark S, Sulkowski, Douglas, Dieterich, Anne, Luetkemeyer, Timothy R, Morgan, Kenneth E, Sherman, Robin, Dretler, Dawn, Fishbein, Joseph C, Gathe, Sarah, Henn, Federico, Hinestrosa, Charles, Huynh, Cheryl, McDonald, Anthony, Mills, Edgar Turner, Overton, Moti, Ramgopal, Bruce, Rashbaum, Graham, Ray, Anthony, Scarsella, Joseph, Yozviak, Fiona, McPhee, Zhaohui, Liu, Eric, Hughes, Philip D, Yin, Stephanie, Noviello, Peter, Ackerman, Atif, Zaman
Publikováno v:
New England Journal of Medicine. 373:714-725
BACKGROUND The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on the efficacy and safety of this combination in patients
Autor:
Katrina L. Oie, John E. Fuchs, Dean T. Martin, Gary E. Pakes, Benjamin Daquioag, Joseph C. Gathe, Vanessa C. Williams, M. Keith Rawlings
Publikováno v:
World Journal of AIDS. :245-251
Objective: The purpose of this study was to investigate whether switching HIV-infected patients stabilized on Trizivir (abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg) plus lopinavir/ritonavir 400 mg/100mg twice daily to Trizivir alone affects c
Autor:
Joseph C. Gathe, Andrew R. Zolopa, Michael S. Gottlieb, Edwin DeJesus, Michael L. Greenberg, Carol Jean Guittari
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:4315-4319
Enfuvirtide is the first fusion and entry inhibitor approved for use for the treatment of human immunodeficiency virus (HIV) type 1 infection and as such represents a novel class of agents. For the population of patients experienced with three antire
Autor:
Philip Lackey, Joseph C. Gathe, Edwin DeJesus, Linda Yau, Christine Katlama, Mark S. Shaefer, Vicente Estrada, Jane Yeo, Benjamin Young, Paul Wannamaker, Schlomo Staszewski, Patrick Yeni, Denise H. Sutherland-Phillips, Joseph J. Eron, Lisa G. Patel, Cindy Vavro
Publikováno v:
The Lancet. 368:476-482
Summary Background Lopinavir-ritonavir is a preferred protease inhibitor co-formulation for initial HIV-1 treatment. Fosamprenavir-ritonavir has shown similar efficacy and safety to lopinavir-ritonavir when each is combined with two nucleoside revers